Project Grant R01HL183505
Award Date 8/10/26
Completion Date 5/31/30
Dollars Obligated $632K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $799,998 to The Trustees of the University of Pennsylvania on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiotropic solid lipid nanoparticles (LNPs) as a drug and biologic delivery platform for cardiac therapeutics. The research focuses on engineering and understanding heart-targeting LNPs that accumulate in cardiac tissue at significantly higher concentrations than existing drug delivery...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $726,531 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify mechanisms of lipid nanoparticle-associated inflammation and reengineer lipid nanoparticles to be non-inflammatory. Lipid nanoparticles have dosed more than one billion patients and enabled delivery of RNA encoding therapeutic proteins for cancer and genetic diseases, but their clinical...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $2,031,250 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop engineered CAR T-regulatory cells (CAR TREGs) targeting myocardial infarction-associated heart failure. The funded research aims to generate CAR TREGs that accumulate in fibrotic, damaged myocardial regions and suppress inflammation to promote healing and improve cardiac function. The work...
- The National Heart, Lung, and Blood Institute awarded $1,137,435 to the University of Pennsylvania on March 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular and inherited disease. The recipient is developing and translating gene-editing therapies across three therapeutic domains. The first targets liver-centered, multiplex editing to prevent atherosclerotic cardiovascular disease through tunable...
- The National Heart, Lung, and Blood Institute awarded The Washington University $550,896 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop targeted nanotherapy for acute myocardial infarction. The project, led by Principal Investigator Jianjun Guan, will encapsulate an engineered secretome derived from naive M0 macrophages into nanoparticles for intravenous administration to simultaneously address three critical post-infarction pathologies:...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $756,607 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research leveraging nutrient sensing and lysosomal degradative capacity in macrophages as a therapeutic approach to cardiovascular disease. The project addresses atherosclerosis, the underlying cause of myocardial infarction, strokes, and heart failure, by investigating dysfunction in the autophagy-lysosome system...
- The National Heart, Lung, and Blood Institute awarded Duke University $814,943 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop non-viral gene therapy approaches for cardiac regeneration following myocardial injury. Duke University will develop cardiac-targeted lipid nanoparticles for in vivo transfection of cardiomyocytes and adapt a cell-state sensing platform (CELLREADR) to deliver therapeutic transgenes with cell-type precision to injured...
- The National Heart Lung and Blood Institute awarded the University of Pennsylvania $169,020 on April 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the genomic and clinical mechanisms of myocardial lipomatous metaplasia and its prognostic implications for cardiac dysfunction and arrhythmia. The recipient will apply a deep-learning segmentation model to cardiac CT images from the Penn Medicine Biobank (23,940 participants with genotypes and imaging as of...
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Institute of Biomedical Imaging and Bioengineering awarded $645,265 to The Trustees of The University of Pennsylvania on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop DNA-loaded lipid nanoparticles (DNA-LNPs) for treating chronic diseases including atherosclerosis and emphysema. The research addresses toxicity barriers that have prevented DNA-LNP development for two decades. Prior...